Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease-Reference-Cited by-全球学者库

Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease

Published:2019-03-06 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Maqsood Usman¹,Ho Terence N²³,Palmer Karen⁴,Eccles Fiona JR⁵,Munavvar Mohammed⁶,Wang Ran⁶,Crossingham Iain⁷,Evans David JW⁸

Affiliation:

1. Sandwell and West Birmingham Hospitals NHS Trust; Department of Respiratory Medicine; Birmingham UK

2. St. Joseph's Healthcare; Firestone Institute for Respiratory Health; Hamilton Ontario Canada

3. McMaster University; Hamilton Ontario Canada

4. Lancashire Care NHS Foundation Trust; NIHR Lancashire CRF; Preston UK

5. Lancaster University; Division of Health Research; Lancaster UK

6. Lancashire Teaching Hospitals NHS Foundation Trust; Department of Respiratory Medicine; Preston UK

7. East Lancashire Hospitals NHS Trust; Blackburn Lancashire UK

8. Lancaster Medical School; Lancaster UK LA1 4YG

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012930.pub2/epdf/full

Reference346 articles.

1. Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: pooled analysis of SHINE and ARISE;Asai;Respiratory Investigation,2016

2. Barnes N Bateman E Gallagher N Green Y Horton R Henley M QVA149 once daily provides superior bronchodilation versus indacaterol, glycopyrronium, tiotropium and placebo: the SHINE study Thorax 2012 A147 [P192]

3. Bateman E Ferguson GT Barnes N Gallagher N Green Y Horton R Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study European Respiratory Journal 2012 509s [2810]

4. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study;Bateman;European Respiratory Journal,2013

5. Dual bronchodilation with once-daily QVA149 provides superior bronchodilation compared to its mono-components and tiotropium in all subgroups of patients with COPD: the shine study;Bateman;American Journal of Respiratory and Critical Care Medicine,2013

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness Analysis of Fixed-Dose Tiotropium/Olodaterol versus Tiotropium for COPD Patients in China;International Journal of Chronic Obstructive Pulmonary Disease;2023-09

2. Pulmonary telerehabilitation vs. conventional pulmonary rehabilitation – a secondary responder analysis;Thorax;2023-07-14

3. Double broncholytic combination of umeclidnium/ vilanterol in COPD therapy: issues of efficacy and safety;Meditsinskiy sovet = Medical Council;2022-10-14

4. Cost-Effectiveness of Umeclidinium/Vilanterol versus Salmeterol/Fluticasone in Elderly Patients with Chronic Obstructive Pulmonary Diseases in China;International Journal of Chronic Obstructive Pulmonary Disease;2022-03

5. Which LABA/LAMA should be chosen in COPD patients in real life?;Pulmonary Pharmacology & Therapeutics;2021-12